The Effect of Subsartorial Saphenous Block on Postoperative Pain Following Major Ankle and Hind Foot Surgery

Sponsor
University of Aarhus (Other)
Overall Status
Completed
CT.gov ID
NCT02697955
Collaborator
(none)
18
1
2
8.3
2.2

Study Details

Study Description

Brief Summary

The study investigates the effect of a ultrasound-guided subsartorial saphenous block on postoperative pain following major ankle and hind foot surgery.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Major ankle and hind foot surgery causes intense postoperative pain. Implementation of continuous sciatic catheters has been a great success in reducing postoperative pain following these operations, but despite an effective sciatic catheter patients still report moderate to severe pain from the anteromedial side of the ankle. According to cadaver dissection studies the saphenous nerve innervates the anterior and medial parts of the ankle and talonavicular joint, and even though a saphenous block is standard procedure in many departments of anesthesiology worldwide, scientific evidence regarding the effect of the saphenous block on postoperative pain is lacking.

This study investigates the effect of a selective, ultrasound-guided subsartorial saphenous block on postoperative pain following major ankle and hind foot surgery.

Study Design

Study Type:
Interventional
Actual Enrollment :
18 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
The Effect of Subsartorial Saphenous Block on Postoperative Pain Following Major Ankle and Hind Foot Surgery
Actual Study Start Date :
Jun 21, 2016
Actual Primary Completion Date :
Feb 28, 2017
Actual Study Completion Date :
Feb 28, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bupivacaine-epinephrine

10 mL of 5 mg/mL bupivacaine with 5 μg/mL epinephrine = 50 mg bupivacaine and 50 μg epinephrine

Drug: Bupivacaine-epinephrine
50 mg bupivacaine and 50 μg adrenalin
Other Names:
  • Marcain-adrenalin (combination drug)
  • Marketing Authorisation Holder: AstraZeneca
  • Marketing Authorisation number: 10213
  • Placebo Comparator: Placebo

    10 ml normal saline water (sodium chloride solution, 0,9%)

    Other: Placebo
    9 mg sodium chloride pr. ml (0,9 %)
    Other Names:
  • Sodium chloride solution
  • Outcome Measures

    Primary Outcome Measures

    1. Frequency of patients who experience significant pain at rest (change from no significant pain to significant pain) [Arrival at the Perioperative Section (within 30 minutes after surgery) and at t = 30 min, t = 45 min, t = 60 min, t = 75 min, t = 90 min, t = 105 min, t = 120. The beginning of the observation period (t0) is the registered time for the end of surgery.]

      Pain scores evaluated using NRS (numeric rating scale). Significant pain is defined as NRS > 3 from the anterior and/medial side of the ankle joint. In case of significant pain, patients receive a rescue saphenous block with 10 ml bupivacaine-adrenaline.

    Secondary Outcome Measures

    1. Sensory testing, infrapatellar branch (nociception is tested using a standardized Neuropen) [At the time point when the patients report a change to significant pain during the observation period. In case of no significant pain during the observation period, sensory testing is conducted at t = 120 min.]

      Test of nociceptive response in the cutaneous innervation area of the infrapatellar branch (branch of the saphenous nerve). The test is performed in an area from the medial femoral condyle to the midline between the apex of patella and tibial tuberosity.

    2. Sensory testing, sciatic nerve (nociception is tested using a standardized Neuropen) [Sensory test is conducted at arrival at the Perioperative Section (within 30 minutes after surgery)]

      Test of nociceptive response in the sciatic cutaneous innervation area to confirm full sensory block of the sciatic nerve.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Elective ankle or hind foot surgery either: (1) total ankle arthroplasty, (2) ankle arthrodesis (3) subtalar arthrodesis or (4) triple arthrodesis

    • Age ≥ 18

    • American Society of Anaesthesiology Classification I-III

    • Informed consent both orally and in writing after the patient has fully understood the protocol and its limitations.

    Exclusion Criteria:
    • Communication problems or dementia

    • Allergies to any medical product used in the study

    • Neuropathy of the sciatic or femoral nerve prior to the operation

    • Morbus Charcot-Marie-Tooth disease, diabetic neuropathy, peripheral vascular disease

    • Daily use of opioids

    • Coagulation disorders

    • Infection at the site of injection or systemic infection

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Anesthesiology, Aarhus University Hospital Aarhus Denmark 8000

    Sponsors and Collaborators

    • University of Aarhus

    Investigators

    • Study Director: Thomas Fichtner Bendtsen, MD, phD, Department of Anesthesiology, Aarhus University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University of Aarhus
    ClinicalTrials.gov Identifier:
    NCT02697955
    Other Study ID Numbers:
    • ProtokolSB2
    First Posted:
    Mar 3, 2016
    Last Update Posted:
    Mar 27, 2017
    Last Verified:
    Sep 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 27, 2017